Melanoma is a rapidly progressing,highly malignancy with limited treatment options and poor prognosis.With the introduction of immunotherapy and targeted therapy,the landscape treatment for melanoma are evolved significantly.Immunotherapy drugs pembrolizumab is a humanized immunoglobulin G4 monoclonal antibody,which can block the immune escape of tumor cells and achieve anti-tumor effect.It has shown potential in monotherapy and combination therapy.This article reviews the pharmacokinetic characteristics,clinical research updates and adverse reactions of pembrolizumab in order to provide a new perspective for the treatment of melanoma.
关键词
黑色素瘤/帕博利珠单抗/药动学/临床研究进展/不良反应
Key words
melanoma/pembrolizumab/pharmacokinetics/clinical research updates/adverse reactions
维普
万方数据